Lung Cancer Prognosis Market Research, Insight, Forecast, Outlook & Analysis by Stratview Reports

Market & Growth Prognosis:
Analysing the market over a period of 2014-17, Stratview Research goes to the crux of the issues shaping the market and estimates the most probable future growth rate for the Lung Cancer Prognosis Market during the period 2018-25.
Stratview Research triangulates the market to grow at a Healthy CAGR over the next five years.

The Diverse Stand Points
The true picture of the market shall not emerge till the time the market is analysed from various point of views. Each vantage point give better understanding of the market. The market of Lung Cancer Prognosis Market has been view from various perspectives such as:
Dissection by Segments
• By Treatment Algorithm : APAC, North America, Western Europe, Rest of The World
• By Demand & Supply : Import, Export
• By Device : Surgical, Monitoring Devices
• By End-User : Decision Maker, Decision Making Process
• By Region

Each view helps us answer a prominent question, and we bring out the best market intelligence which is of interest to each and every player in the market, no matter where he lies in the value chain.

To get the feel of how our best in class, cutting-edge market research report feels, request a sample:
https://www.stratviewresearch.com/Request-Sample/425/lung-cancer-prognosis-market.html

Lung Cancer Prognosis – The Global Lung Cancer Management Market in 2019
For the first time in market, one report exclusively touches upon the demands, gaps and opportunities of the global lung cancer market while covering Lung Cancer Diagnostics, Lung Cancer Therapeutics, Lung Cancer Nutritional supplement, Lung Cancer Surgery and Lung Cancer Connected Health Market. The management of Lung cancer varies with region, by decision makers, by site of treatment, by type of lung cancer, by age, by decision making process, by cost of therapy at each stage and by various other parameters. Why Lung Cancer? Because WHO and other health agencies consider it to be the number One killer across the world.

If we consider the Lung Cancer Management Market from the stakeholder’s perspective, then drugs approved for Small Cell Lung Cancer will not be applicable for Non-Small Cell Lung Cancer. What is the future of the top 10 best-selling drugs in this segment, will they stay or fade away? Among the class of drugs, will Angiogenesis Inhibitors take a dip in sales by 2025 or will it overtake the sales of drugs in the class Immune Checkpoint Inhibitors? What is the market for BRAF / MEK Inhibitors? Who all are the active players and who are newbies. Will the differential cost of therapeutics across the regions impact the drug sales in North America versus APAC? In the Small Scale Lung Cancer Therapeutics, immunotherapy drugs will play a major role in the next 7 years and may grow a CAGR of 7.44% globally however the same class of drugs might grow at a CAGR of 10.59% in the Non-Small Scale Lung Cancer Therapeutics Market in the same time period.
Considering that all the drugs mentioned above have a bright future till 2025, how many companies would like to compete in this market. How will the new joiners react if they consider that the market had a potential of USD 17.11 Billion alone in 2018 and is likely to grow at a CAGR of 8.28% globally till 2025.

In the Lung Cancer Diagnostics segment, Thermofischer, Roche, Biomerieux are few of the market leaders but are they going to get tougher competitions from the newbies such as Astraeus Technologies, Zebra Medical, Deton, Oncocyte and many more that are entering the specialized diagnostics market. It might be interesting to consider that while 50% of the oncologists decide (decision makers) the type of tests and the frequency of repeat tests, shared decision making process is equally high among the Lung Cancer Management Market. The opportunity is huge, NSCLC cases accounts for 85% of the recorded lung cancer incidence worldwide, > 60% require diagnosis, medicine for maintenance, pain and other side effects.

Considering the complications and limitations in lung cancer surgery (not all patients are eligible), still the market is expected to grow steadily at a CAGR of 6.29%, over the course of forecast period (2019-2025). The demand for NSCLC surgery is high, thus the market size of 99%. In some cases surgery is not recommended, when the tumor is found in proximity with the heart, the esophagus – the food pipe, the wind pipe and major blood vessels. The demand for NSCLC surgery is expected to grow rapidly with a CAGR of 6.31% over the course of seven years. The study on the Lung Cancer Management Market by Stratview also states that Lobectomy (sub segment under Lung Cancer Surgery) results in lowest recurrence rate and higher survival rate as compared to other surgery type. Hence it is the highly referred type of surgery procedure for NSCLC cases. One of the companies, Auris is most promising in this segment and has a brighter future ahead. This segment also foresees competition from Chinese companies such as IFLYTEK who are strong contenders in the global market.

Among the different segments of Global Lung Cancer Management Market, connected health or Apps for Lung cancer maintenance or management are few. However, the segment is promising, as researchers believe that App based software can help in treatment adherence, keeping track of medical records (insurance companies, medical centres). Developed markets such as USA, UK, Germany, France, Japan, China and Australia are the near term opportunities.

Lung cancer patients need nutritional supplements throughout their treatment phase followed by recovery and maintenance phase. The study from Stratview Research also looks at the aspects of sales and marketing, buying patterns of end users which can help companies such as Abbott, Danone, Nestle, B Braun and more gauge the market and look at the changing preferences of the market in regions such as Asia Pacific, Europe and North America.

Finally the report on Lung Cancer Prognosis also focuses on the regional aspects and gives the reader the flexibility to consider between global market as whole or regions in particular. It is imperative to look at this market as connected as out of the prevalent cases of Lung cancer are potential candidates of diagnosis and of the diagnosed pool a higher percentage will require medication or surgery, there will be few drop outs and few gaps, more or less all the above will need apps or Healthcare IT products to monitor drug adherence, doctor access, and above all long term nutritional supplement.

The Report Highlights:
The Research Report offers a detailed look into market, its robust growth perspective, the factors influencing the industry, the competition intensity and a peek into the future.
The following are the key features of the report:
● Strategic segmentation
● Market analysis: Growth drivers and constraints, Porter’s five forces
● analysis, SWOT analysis
● Detailed Competitive Rivalry landscaping
● Market trend and forecast analysis
● Future Growth Boulevards

Click Here for Other Reports from Stratview Research in the Healthcare & Life Science Industry:
https://www.stratviewresearch.com/market-reports/Healthcare-and-Life-Sciences.html

Stratview Research
400 Renaissance Center,
Suite 2600,
Detroit, Michigan, MI 48243
United States of America
Phone No. +1-313-307-4176
sales@stratviewresearch.com

Stratview Research is a global market intelligence firm offering a wide range of services including syndicated market reports, consulting, sourcing intelligence, and customer research. We are a trusted brand in the research industry with capability of commissioning complex projects within a short span of time with high level of accuracy.

This release was published on openPR.